BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT)

Historical Holders for Q3 2025

Type / Class
Equity / COMMON STOCK
Symbol
BBOT on Nasdaq
Shares outstanding
80,458,364
Price per share
$11.58
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
56,812,363
Total reported value
$657,547,712
% of total 13F portfolios
0.01%
Share change
+56,812,363
Value change
+$657,547,687
Avg buy value change
+0.01%
Number of holders
41
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Helix Holdings II LLC 23% $168,952,713 17,878,594 Bihua Chen 11 Aug 2025
BridgeBio Pharma LLC 18% $131,152,335 13,878,554 BridgeBio Pharma LLC 11 Aug 2025
Flynn James E 6.2% $46,167,465 4,885,446 Deerfield Management Company, L.P. 11 Aug 2025
BC Global Opportunities IX LP 5.5% $41,256,309 4,365,747 BC Global Opportunities IX LP 04 Sep 2025
CITADEL ADVISORS LLC 3.2% $29,112,489 2,538,142 Kenneth Griffin 30 Sep 2025
Adage Capital Management, L.P. 1.9% $17,063,013 1,487,621 Adage Capital Management, L.P. 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% $10,151,432 885,042 T. Rowe Price Associates, Inc. 30 Sep 2025
As of 30 Sep 2025, BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT) has 41 institutional shareholders filing 13F forms. They hold 56,812,363 shares. of 80,458,364 outstanding shares (71%) .

Top 25 institutional shareholders own 69% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Cormorant Asset Management, LP 22% 17,878,594 14% $207,034,119
DEERFIELD MANAGEMENT COMPANY, L.P. 6.1% 4,885,446 0.87% $56,573,465
Omega Fund Management, LLC 4.1% 3,289,661 17% $38,094,274
WELLINGTON MANAGEMENT GROUP LLP 3.7% 2,961,263 0.01% $34,291,426
Alphabet Inc. 3.5% 2,823,126 1.4% $32,691,799
EcoR1 Capital, LLC 3.5% 2,823,126 1.6% $32,691,799
ENAVATE SCIENCES GP, LLC 3.3% 2,626,946 9.3% $30,420,035
CITADEL ADVISORS LLC 3.2% 2,538,141 0.02% $29,391,673
BlackRock, Inc. 2.5% 2,048,552 0% $23,722,232
NOVO HOLDINGS A/S 2.4% 1,961,317 1.5% $22,712,051
Paradigm Biocapital Advisors LP 2.3% 1,866,141 0.64% $21,609,913
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.8% 1,487,621 0.03% $17,226,651
EVENTIDE ASSET MANAGEMENT, LLC 1.3% 1,082,362 0.2% $12,414,692
Laurion Capital Management LP 1.3% 1,045,800 1.7% $12,110,364
Octagon Capital Advisors LP 1.3% 1,043,110 1.9% $12,079,214
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% 885,042 0% $10,249,000
VANGUARD GROUP INC 0.8% 647,599 0% $7,499,197
Aisling Capital Management LP 0.7% 564,625 1.4% $6,538,358
GEODE CAPITAL MANAGEMENT, LLC 0.67% 541,602 0% $6,274,554
ADAR1 Capital Management, LLC 0.62% 501,228 0.58% $5,804,220
SILVERARC CAPITAL MANAGEMENT, LLC 0.57% 457,414 0.77% $5,296,854
ARMISTICE CAPITAL, LLC 0.51% 412,000 0.15% $4,770,960
MILLENNIUM MANAGEMENT LLC 0.46% 369,563 0% $4,056,288
Casdin Capital, LLC 0.35% 282,312 0.27% $3,269,173
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.35% 279,350 0% $3,234,873

Institutional Holders of BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q3 56,812,363 $657,547,712 +$657,547,687 1,158% 41